The device was not included as a potential treatment despite sham-controlled evidence showing it reduces patient symptoms.

With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

More than ever, early-career physicians are looking for ways to fill gaps left by traditional education while maximizing ...

The year had a lot to offer, from advanced therapies aimed at Lp(a), GLP-1, and other targets, to support for simpler ...

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

Both EACTS and STS have taken measures against bullying, disrespect, and other harmful behavior. Others may follow suit.

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top 10.

TCTMD reported in-depth on the FAVOR III Europe trial, October 30, 2024, at the TCT 2024 meeting. The full manuscript was subsequently published in EuroIntervention in January 2025. The published ...